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ABSTRACT
The World Health Organization reported that the SARS-CoV-2 virus has infected more than 5 million people around 
the world. Dental care providers and health care professionals need to be aware of the high-risk potential of cross-
infection since the routes of virus transmission commonly happen through droplets and aerosols. This review aimed 
at collecting essential knowledge about the COVID-19 needed by dental practitioners. The review focused on the oral 
involvement in COVID-19, the role of oral transmission as the high-risk potential of cross-infection and recommended 
strategies to minimize the risk of cross-infection in dental practice. We searched all the published clinical features 
from PubMed, Google Scholar, Scopus and hand searched library online databases, from January 2015 until May 
2020. Keywords used were “COVID-19”, “Dentistry”, “Dental protection”, “Cross-contamination”, “Aerosol and non 
aerosol”, and ”Povidone-iodine” with their combinations. We identified 52 articles to review after the initial selection with 
inclusion and exclusion criteria. Results showed use of topical applications of povidine-iodine and viricidal mouthwash 
could significantly reduce the high-risk of cross-infection from dentistry patients who are asymptomatic with COVID-19 
infection. Further safeguards include suspending all non-emergency procedures temporarily and closely screening 
patients for symptoms which may be suspected to be COVID-19 infection. 
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Corona Virus Disease 2019 (COVID-19) on March 
11, 2020 was determined by the World Health 
Organization (WHO) as a worldwide pandemic. 
Based on WHO data up to 24th of May 2020, the 
number of patients confirmed to be positive of CO 
VID-19 has reached to over 5.17 million cases with 
336,430 patients who are have died. The patients 
confirmed positive with COVID-19 in Indonesia 
were announced by the Government of Indonesia 
on March 2, 2020, and subsequently on March 14, 
2020, after local transmission was reported, the 
Corona virus was designated a national disaster. 
Based on data taken from the COVID-19 Rapid 
Response and Prevention Cluster up to 24th of May 
2020, the number of positive confirmed patients 
reached 18,496 with more than 1372 mortalities.1,2 
Considering the source of the spread of COVID-19 
tends to be through droplets and aerosols, every 
patient who has been cared for by dental care 
providers is at a potential high-risk for the spread 
of COVID-19.3
In addition, the development of COVID-19 
management in the field of dentistry currently 
focuses on how to handle droplets and aerosols 
which arise when examinations and treatments are 
carried out. Dar Odeh (2020)3 and Lo Giudice et al. 
(2020)4 stated that the determination of the service 
type only in the emergency and elective cases 
has been established as a form of protection for 
the spread of COVID-19. However, these present 
conditions cannot last long, and it is unknown when 
the pandemic will end and even then, it still retains 
the potential to re-emerge with a more dangerous 
form which includes the possibility of mutations 
of the Severe Acute Respiratory Syndrome 
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Coronavirus 2 (SARS-CoV-2), the virus which 
causes COVID-19.5
The SARS-CoV-2 virus binds to its receptors, 
the angiotensin-converting enzyme 2 (ACE2) which 
are abundant on the surface of the mucosal epithelial 
cells in the nasal cavity, nasopharynx, oral mucosa, 
eyes and tongue as well as in the gastro-intestinal 
tract, kidneys, liver and heart. Accordingly, saliva 
as a liquid which lubricates the mucosal surface 
of the oral cavity is a main source of COVID-19 
infection. The potential of infection increases in 
the elderly, people with hypertension, diabetes 
mellitus, immunocompromised and patients with 
chronic respiratory problems. Additionally, SARS-
CoV-2 infection will stimulate the immune response 
of IgM and IgG formation, which are very volatile, 
and currently, there have been no research reports 
on the formation of adaptive immune responses.6 
Considering that up to now, there have not been 
any standardized vaccines and drugs found to 
prevent and treat COVID-19, then what needs 
to be especially noticed is that there are some 
COVID-19 patients who are confirmed to have no 
symptoms. Regarding these asymptomatic carriers 
of COVID-19, the dental community needs to be 
properly alerted and informed of the best practices 
for prevention of COVID-19 transmission and cross-
infection. 
This review aims to report any evidence of 
the high-risk potential of COVID-19 cross-infection 
in dental practice and strategy to prevent virus 
transmission in a clinical setting. The focus of this 
review was the oral involvement in COVID-19, the 
role of oral transmission as the high-risk potential 
of cross-infection and recommended strategies for 
dental care providers and health care professionals 
to minimize the risk of cross-infection in dental 
practice. A literature search was performed to find 
52 relevant articles published in PubMed, Google 
Scholar and Scopus during January 2015 until 
May 2020 according to six search terms which 
are “COVID-19”, “Dentistry”, “Dental protection”, 
“Cross-contamination”, “Aerosol and non-aerosol”, 
and ”Povidone-iodine. Additional references were 
identified by a manual search from the library 
online among the references. The inclusion criteria 
were all types of articles related to the selection of 
keywords, full text available and only in human. The 
grey literature was excluded.
Based on a thorough review of the current 
selected literatures, the best preventive actions 
which can be taken now to prevent any further 
transmission are by closely screening the patients 
and controlling infection.4 Besides these best 
practices, Flor (2020)7 mentioned that the use of 
antiseptic mouthwash needs to be considered as 
a national movement to prevent transmission of 
COVID-19. Along with these recommendations, the 
review of related articles showed the importance of 
using povidone-iodine with the right concentration to 
reduce the spread of SARS-CoV-2 virus infection.7
What are the symptoms and mechanisms of 
COVID-19 in multiple organs? 
General pathogenesis
The SARS-CoV-2 viruses are comprised of a 
spike-shaped cell membrane enveloped with single 
positive-stranded RNA as their genome which 
causes symptoms ranging from colds to extreme 
respiratory, hepatic and neurologic symptoms. 
Currently, there are six other corona viruses which 
are reported to attack humans. It is reported that 
SARS-CoV-2 has closer nucleotide-sequence 
similarity with SARS-CoV (about 79%) compared 
with MERS-CoV. The main difference between 
SARS-CoV-2 and SARS-CoV lies on the ORF1a 
gene and S-protein gene. The binding of SARS-
CoV-2 virus to ACE2 receptors on the surface of the 
host cells initiating the pathogenesis of COVID-19 
is followed with the penetration of the virus into its 
cytoplasm, starting the cascade of protein synthesis 
to produce the structural components that the virus 
needs to form the infectious virions.8 Here we 
propose a schematic mechanism by which the virus 
infects human cells to initiate inflammation and cell 
death based on recent published systematic review 
and research articles from the outstanding journals 
(9-14). The progress of the disease is schematically 
illustrated in Figure 1.
The release of IgM and IgG antibodies triggered 
by activating an immune response becomes the 
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basis for rapid antibody detection tests on the 
patients suspected of being positively infected with 
SARS-CoV-2 virus. The IgM antibodies are first 
produced by plasma cells on day 3 to day 6, then 
will disappear after a few weeks. The IgG antibodies 
are produced a couple of days later as a result of 
antibody class switching and maturation.11–13 The 
immune body response to SARS-CoV-2 infection 
helps patient to self-recover from the disease. 
However, a different pathway is likely to occur 
for the patients who have an immune response 
disorder, since its excessive immune response may 
trigger other systemic pathologies. Another harmful 
condition is pyroptosis which can trigger leakage of 
blood vessels causing death.10
The SARS-CoV-2 virus has the advantage of 
genetic diversity and rapidly mutates and evolves 
which can affect its pathogenesis.14 This mutation 
has implications for future challenges in developing 
a vaccine.5
Manifestations of COVID-19 
The incubation periods for COVID-19 are 
approximately 5-6 days and can be up to 14 
days. During this time, the symptoms have not 
yet appeared, but the infected patient can be 
contagious.15 The symptoms of COVID-19 have a 
wide range from mild or without symptoms to severe 
respiratory illness accompanied by multiple organ 
failure. We summarize systemic manifestations of 
COVID-19 from recent review articles, a clinical 
case report and research article (Table 1).16-26 These 
symptoms indicate that COVID-19 not only affects 
the respiratory system but also involves multiple 
organs. The damage of organs is not merely by 
the viral infection itself, but it is largely due to a 
strong inflammatory response known as a cytokine 
storm. The previous condition of the patients also 
significantly contributes as comorbidities including 
hypertension, cardiovascular disease, diabetes 
mellitus, malignancy, chronic pulmonary, liver, and 
Figure 1. The simplified mechanism which schematically illustrates the infection cascade of SARS-CoV-2. The target cells of this 
virus are epithelial cells lining the respiratory tract, alveolar, endothelium blood cell and lung macrophage which present ACE2 
receptors on its surfaces.9 The infection of host cells initiates inflammation and involves a sequence of cellular events to rapidly 
bring blood-borne host defenses including macrophages and PMN to attack the virus.10 The dendritic cells phagocytose the virus 
and the viral peptides are displayed on the surface of MHC class II molecules to be recognized by cell T helpers. The activation of 
the T cell helpers results in cytokine production and enables other immune responses: Antibodies IgM and IgG released by plasma 
cells derived from activated B cell can block the virus from infecting cells as well as mark the virus for destruction. Following this, 




proceed to dental procedures after undergoing a series of pre-treatment procedures (Figure 2). 
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kidney disease.16 The patients with comorbidities 
have a higher risk to be infected and have a higher 
fatality rate.
What is the oral involvement in COVID-19?
The oral cavity is one of the potential port-entries 
for the SARS-CoV-2 virus into the body through 
the ACE2 receptor binding sites found in oral 
epithelial tissues. Furthermore, it was confirmed 
that the SARS-CoV-2 virus was present in the 
saliva of infected COVID-19 patients. A recent case 
study reported oral manifestations of COVID-19. 
The oral symptoms that have been reported 
in patients confirmed positive with COVID-19 
include a decreased sense of taste in the early 
stages, pain, desquamative gingivitis, ulcer, and 
blistering.27 The decreasing sense of taste is an 
interesting phenomenon and it may relate with the 
Table 1. The manifestation of COVID-19 in multiple organs
Organ Mechanism Sign and Symptoms
Respiratory system The main route of SARS-CoV-2 infection is through the nasal cavity 
targeting the main respiratory tract. After reaching this area, the virus will 
bind to several types of non-neuronal cells in the olfactory area which 
expresses ACE2 and transmembrane protease, serine 2 (TMPRSS2) 
so that those replicates and accumulate in these cells. This process 
underlies the reported olfactory disorders (decreasing of smell) in the 
initial phase of viral infection.17
In addition, the virus will spread to the surrounding cells in the upper 
respiratory tract (nasal cavity and pharynx). Then, this virus continues 
to infect the lower respiratory tract. The greatest damage to the lower 
respiratory tract is in the apical and distal parts. For that reason, ACE2 is 
highly expressed in type 2 of pneumocytes cells which are in the alveolar 
area. Additionally, alveolar areas also contain alveolar macrophages 
and dendritic cells which will mediate the immune response against the 
virus.18 The severe symptoms of acute respiratory distress syndrome 
(ARDS) occur due to over-activation of the immune response. Death 









Symptoms in the gastrointestinal system are reported in patients in 
the early and mild phase of COVID-19 before respiratory symptoms 
appear. ACE2 is found in the digestive tract namely in the pharynx, 
esophagus, gastric, and intestines.20 Viral nucleocapsid proteins are 
also found in the cytoplasmic epithelium in the gastric, duodenum and 
rectum. The viral nucleic acids are also found in the stool. These facts 
may support that the virus directly infected the gastrointestinal system. 
Liver involvement in COVID-19 is not caused by a direct effect of virus 
infection to the hepatocytes because ACE2 is only found in bile duct 
cells and is discovered to be very minimal in hepatocytes. The liver 
disorder is by an indirect effect due to psychological stress, systemic 




Abdominal pain / discomfort
Nervous system The involvement of the nervous system in COVID-19 is reported to 
occur in the periphery and central nervous system (CNS) from mild 
(anosmia and ageusia) to severe (encephalopathy). The mechanism 
of anosmia (decreasing sense of smell) and ageusia (decreasing 
sense of taste) have been explained above. The movement of the 
virus to the brain may originate from the nasal cavity that may move 
via the cribriform plate to the area around the olfactory bulb. Thus, 
the discovery of anosmia must always be followed by examining the 
possibility of involvement of the SARS-CoV-2 infection in the CNS. The 
other mechanism of CNS involvement in COVID-19 is via the blood 
circulation. SARS-CoV-2 presence in circulation interacts with ACE2 
expressed in endothelium and damage the endothelial lining. This leads 
to rupture of the cerebral vascular and bleeding within cerebral tissue. 
Furthermore, by circulation, the virus reaches the brain and interacts 
with ACE2 expressed in neuronal tissue and initiates a cycle of viral 
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higher expression of ACE2 on the tongue where 
most of the taste buds are located.28 The high viral 
load in saliva (and possibly in the salivary gland) 
will increase the likelihood of viral attachment and 
infection to the tongue epithelia.3  By using RNA-
seq profiling data analysis Xu et al. (2020) reported 
that ACE2 receptor found in oral epithelial tissues.28 
The SARS-CoV-2 virus may bind and infect gingiva 
and another oral mucosa through ACE2 receptors 
which is expressed in this area causing symptoms 
such as pain and lesions which are very similar to 
other viral lesions such as foot and mouth disease 
and herpes.27
What is the role of oral transmission as a high-
risk potential of cross-infection?
Previous studies suggested that the oral cavity may 
play a significant role in COVID-19 transmission 
and bring a high-risk potency of cross-infection 
in dental treatment.19,29,30 The SARS-CoV-2 can 
be transmitted directly from person to person 
through the oral cavity in the form of droplets (when 
coughing or sneezing), aerosols (due to several 
dental procedures, nebulizers, and others), and 
direct contact or indirectly through medical and non-
medical equipment. The viral particles in droplets 
(size of >5 um) can be transmitted at <1-meter 
distance while in aerosols (size of ≤5 um) can be 
transmitted through the air (airborne) at a greater 
distance of >1-meter.29 There is emerging evidence 
suggesting that the body parts (hand, oral, nasal and 
eye mucous membrane) or fomites contaminated 
with the droplets may become a transmitting route 
of cross-infection.19 Although there was a report of 
patients with conjunctival disorders, the evidence 
of involvement the conjunctival mucosa in the 
COVID-19 infection route has not been significant, 
since the ACE2 expression in the conjunctival is 
almost non-existent.30
What are the recommended strategies to 
minimize the risk of cross-infection in dental 
practice?
Patient screening and comprehensive dental 
management
The steps of patient dental management are 
arranged in adherence to a number of infection 
prevention and dental emergency treatment 
protocols adopted from the Centers for Disease 
Control and Prevention (CDC), the Department of 
Health and Human Services USA, WHO, and the 
Coronavirus Center for Dentists in the American 
Dental Association (ADA) as an effort to prevent 
and minimize the risk of cross-infection. The 
schematic steps of the screening phase until the 
management of dental care preparation and the 
protocols referred to in each stage can be seen 
in Figure 1. The schematic flowchart describes in 
detail each stage which is generally divided into 
two main sequential stages, starting from initial 
screening (non-contact phase) followed by pre-
treatment stage (contact phase).
Initial screening
The initial screening of dental patients is done on a 
non-contact basis. Patient is directed to fill out an 
online questionnaire sent via email or on a website. 
An initial assessment is conducted to determine the 
Organ Mechanism Sign and Symptoms
Cardiovascular Cardiovascular manifestations in COVID -19 occurs in around 30% 
of hospitalized patients contributing to approximately 40% of deaths. 
Although the exact mechanism of cardiac injury is not yet fully 
understood, the cardiac injury possibly occurs through 3 mechanisms: 
1) viral infiltration into myocardial tissue resulting in cardiomyocyte 
death and inflammation, 2) cardiac stress due to respiratory failure and 
hypoxemia, and 3) cardiac inflammation secondary to severe systemic 
hyper inflammation.24 
The role of ACE2 in cardiovascular disease remains controversial. 
ACE2 is an ACE homologue, but it acts as a counterbalance in the renin-
angiotensin-aldosterone system (RAAS) in maintaining cardiovascular 
homeostasis. SARS-CoV-2 infection causes downregulation of ACE2 







Majalah Kedokteran Gigi Indonesia. April 2020; 6(1): 1 – 15
ISSN 2460-0164 (print)
ISSN 2442-2576 (online)
Figure 2. An initial dental patient screening for COVID-19 and follow up plan for dental management
 
Figure 2. An initial dental patient screening for COVID-19 and follow up plan for dental management 
 
  
status of the patient’s risk level of getting exposed 
to COVID-19. The evaluation results of initial 
screening assessment that consists of patient’s risk 
status of COVID-19 exposure and management of 
dental treatment that is appropriate for the patient’s 
condition are communicated to the patient via tele- 
or video-consultation.31 
The follow-up management of the dental care 
is determined based on the results of the initial 
stage evaluations. If the results show any indication 
of a COVID-19 positive suspect, then the patient 
will be referred to undergo a series of further 
tests to establish the diagnosis. Elective dental 
procedures can be postponed for at least the next 
14 days, and urgent cases with pain symptoms can 
be prescribed with antibiotics and/or analgesics. 
For suspected COVID-19 patients in an emergency 
status or whose status has escalated from urgent 
level, dental procedures can be carried out with 
strict protocols for handling and preventing cross-
infection risk; both the protocol of health facility 
requirements to be used for treatments and the 
protocol of emergency treatments. Patients with 
negative COVID-19 indication can proceed to 
dental procedures after undergoing a series of pre-
treatment procedures (Figure 2).
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Table 2. Detailed medical history form consists of COVID-19 screening questionnaire and assessment of emergency status for the 
dental patient
 
Table 2. Detailed medical history form consists of COVID-19 screening questionnaire and assessment of emergency status for 





























Dental treatments on patients with COVID-19 
negative indication can be performed by following 
further screening protocol. At this stage, a 
subjective examination is done by filling in the 
patient’s answers into a specific medical record to 
screen for more accurate possibilities of the risk of 
being infected with COVID-19 and to conduct an 
initial evaluation of the possibility of emergency 
dental status. The list of questions in the specific 
medical record can be seen in Table 2.
Following complete filling of the medical record 
data, the patient’s body temperature is then checked 
using non-contact thermometer or thermometer 
equipped with an infrared thermal sensor camera29 
to identify the risk of body temperature increase that 
may indicate an infection. Subjective examination 
procedures and body temperature measurements 
can be performed by dentists assisted by trained 
medical staffs with reference to the protocols of 
COVID-19 emergency prevention and treatment. 
Dentists and medical staffs must wear personal 
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protective equipment (PPE) recommended 
by CDC standards (Figure 3) and follow hand 
hygiene procedures.32 During the examination and 
measurement procedures, the patient is required 
to wear a mask and follows self-protection protocol 
by covering the mouth and nose with tissue when 
sneezing or coughing.33 Patient suspected of 
COVID-19 must be placed in a separate room with 
adequate ventilation and a minimum distance of 6 
ft (2 meters) from other patients, according to the 
guidelines recommended by the CDC.34
If the body temperature is > 100 °F = 38 °C 
accompanied with symptoms of acute respiratory 
problems, non-emergency dental treatments can 
be postponed for at least the next 14 days, and 
the patient is then referred for an antibody and 
viral testing,36 followed by infection treatments for 
COVID-19 suspects at the referral hospital. For 
emergency cases, further treatments need to be 
carried out at health facilities that have negative 
pressure rooms conforming to the regulations 
for prevention and management of COVID-19 
infectious disease cases.33
Patient management and prevention of cross-
infections in dental clinics
Protocols of infection prevention and control need to 
be strictly implemented during the clinical treatment 
of dental patients. Droplets and aerosol sprays from 
saliva during dental procedures have been reported 
as sources of SARS-CoV-2 transfer that has the 
potential to cause cross-infection of COVID-19.29 
Several of the strategies that can be applied to 
minimize the risk of cross-infection during dental 
treatment, especially for some procedures that have 
the potential to produce droplets and aerosols, can 
schematically be seen in Table 3.
The WHO and several other world 
organizations have issued a number of online 
guidelines and protocols that are accessible 
via their websites and are recommended to be 





















Figure 3. Centers for Disease Control and Prevention recommendations for putting on and removing personal protective 
equipment (PPE) for treating COVID-19 patients.35 
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Figure 3. enters for isease ontrol and Prevention reco endations for putting on and re oving personal protective 
equipment (PPE) for treating COVID-19 patients.35
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effort to prevent and control cross-infection.41–43 On 
March 16, 2020, the American Dental Association 
(ADA) released a recommendation to postpone 
treatment and non-emergency dental procedures.42 
For emergency cases which require urgent 
treatments during the COVID-19 pandemic, the 
possible clinical procedures that can be adopted 
are elaborated in Table 4. The management of 
treatments which are summarized in Table 4 are 
restricted to minimally invasive approaches and 
could be dynamically adjusted as the COVID-19 
outbreak develops in their respective regions. 
Dental health care professionals should regularly 
consult their state dental boards and state or local 
health departments for current local information for 
requirements specific to their jurisdictions.
During the COVID-19 pandemic, these 
emergency conditions need to be taken into 
consideration, especially the conditions of patients 
suspected of or who have tested positive for SARS-
CoV-2. By strictly implementing the protocols, it is 
expected that the potential risk of cross-infection 
can be avoided. 
It is still uncertain whether a vaccine can be 
invented in the near future and whether the vaccine 
will be able to optimally prevent COVID-19 infection. 
Strategies that can be effectively and immediately 
implemented as a new protocol for the ‘new 
normal’ era need to be applied as soon as possible 
during this period in which the risk of SARS-CoV-2 
exposure continues. Medical staff and dental care 
institutions need to be properly prepared because 
it has been predicted that the number of patients 
visiting dental clinics will surge as soon as the 
restriction of general treatment during the pandemic 
emergency is lifted. 
Recommended strategies applied recently 
and toward the ‘new-normal’ future dental 
management and treatment
Systemic treatment management of COVID-19 
cases is still being studied as well as innovations 
related to curative, rehabilitation, and prevention 
methods. Additionally, alternative therapies and 
preventive actions are needed both for patients 
and healthcare providers.45 We analyze important 
evidences provided in systematic review, research 
reports, and letter to journal editor to show and 
recommend the importance of gargling as one 
treatment and prevention approach.7,45-50 Recently, 
the use of povidone-iodine (PVP-I) has been 
recommended and discussed due to its potential 
as an antivirus agent for general and dental care 
procedures. Closely related to the mechanism 
of virus infection into the upper respiratory tract 
through the oral cavity to the nasopharyngeal area, 
oral hygiene is very important to be maintained by 
both patients and healthcare providers. Povidone-
iodine mouthwash diluted by 1:30 (equivalent to 
0.23% PVP-I) is proven to be effective in vitro as an 
antivirus against MERS-CoV and SARS-CoV-1,46 
with antivirus ability of ≥ 99.99%, and is also 
recommended as mouthwash or nasal spray for 
COVID-19 local treatment or prevention.47 SARS-
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Table 3. Recommended strategies and protocols for preventing cross-infection of COVID-19 in several dental procedures 
Prevention Strategies Treatment precautions
A. Using rotary instruments:
1. Place rubber dam37
2. Use salivary suction37
3. Use aerosol box for cavity preparation with high speed 
air-turbine handpiece38
4. Clean regularly and sterilize the Dental Unit Waterlines 
(DUWLs) using certain antiseptic39
Strategies to prevent cross-infection in using rotary instrument 
can be implemented in a number of cases such as: 
1. Treatment of root canals in endodontic cases. This procedure 
uses many tools that have a potential to be sources of cross-
infection from saliva droplets that contaminate the tools and 
surface of area around the dental unit (inanimate surface)37
2. Cavity preparation with high speed air-turbine handpiece40
3. Ultrasonic scaling and polishing40
B. No-rotary instrumentation
1. Using Atraumatic Restorative Techniques (ART)
2. Chemochemical caries removal
Strategies for using no-rotary instruments can be implemented in 
the following cases: 
1. Selected cases of restorative dentistry
2. Pediatric dentistry 
3. Manual scaling and polishing 
10
Majalah Kedokteran Gigi Indonesia. April 2020; 6(1): 1 – 15
ISSN 2460-0164 (print)
ISSN 2442-2576 (online)
Table 4. Management of acute dental problems during COVID-19 Pandemic44
Symptoms Managements
Acute apical abscess o Recommend analgesic, prescribe antibiotic if found an infection symptom
o Asked patient to call back in 48-72 hours if their symptoms have not resolved
Acute periodontal abscess o Recommend analgesic, prescribe antibiotic if found an infection symptom.
o Asked patient to call back in 48-72 hours if their symptoms have not resolved
Acute pericoronitis o Recommend analgesic, prescribe antibiotic if found an infection symptom.
o Asked patient to call back in 48-72 hours if their symptoms have not resolved
o Recommend chlorhexidine or warm salt-water mouthwash
Necrotising ulcerative gingivitis/periodontitis o Recommend analgesic, consider antibiotic (metronidazole is a drug first 
choice)
o Recommended chlorhexidine or hydrogen peroxide mouthwash
o Advice to maintain good oral hygiene advice
Reversible pulpitis o Recommend analgesic
o Advice to avoid hot and cold foods and beverages
o Asked patient to call back if the symptoms get worse.
o Advice patient to use an emergency temporary repair kit (purchase online or 
at the pharmacy)
Irreversible Pulpitis o Recommend analgesic
o Asked patient to call back if the symptoms get worse
Dentin hypersensitivity o Avoid noxious stimuli (cold or acidic foods and beverages)
o Regularly apply desensitizing toothpaste to the area with a finger
Dry Socket o Recommend analgesic
o Recommend warm salt-water mouthwash
o Prescribe antibiotics for an immunocompromised patient and patient if 
emerging signs of spreading infection or systemic infection
o Refer to urgent dental care for dressing if the pain gets worse
Post-extraction hemorrhage o Advise patient not to split or rinse
o Washout blood excess by rinsing with warm water
o Place cotton roll or gauze swab moistened with saline or water over the 
socket, bite firmly for 20 minutes, check bleeding after 20 minutes and repeat 
if necessary
o After bleeding stops, advice patient not to drink alcohol, smoking or exercising 
for 24 hours
Oral ulceration o If ulceration has been present for less than 3 weeks:
•	 Recommend analgesic
•	 Advice chlorhexidine mouthwash (not for children under 7 years old)
•	 Take soft diet
o If ulceration due to denture, remove denture where possible
o If trauma from an adjacent tooth cause ulceration, advise a patient to use 
a temporary emergency filling. Suggest a patient purchase at pharmacy or 
online
o Prescribe antiviral agents if needed
o Refer a patient to dental emergency care if ulceration has been present for 
three weeks or more
Cracked, fractured, loose or displaced tooth 
fragments and restorations
o For broken or fractures teeth or filling:
•	 Advice patient to use a temporary emergency filling if a tooth is sensitive. 
Suggest a patient purchase at pharmacy or online.
•	 Recommend analgesic
•	 Advice patient to call back if the symptoms have not been relieved
o For broken crowns, bridges and veneers:
•	 Advice patient to use a temporary emergency filling. Suggest a patient 
purchase at pharmacy or online
•	 Recommend analgesic if a patient has painful symptoms
•	 Refer to emergency care if a patient has inhaled a piece of tooth
11
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Symptoms Managements
Ill (pain) fitting or loose denture o Recommend analgesic
o Advice the patient to remove their denture whenever possible
o Advice patient to visit routine dental care when the service is back to normal
Trauma from fractured or displaced 
orthodontics appliances
o Direct patient to www.bos.org.uk website for advice on managing orthodontics 
problem
o Refer to emergency care if a patient has inhaled or ingested a large part of 
an appliance 
Dento-alveolar injuries o If the patient not in an emergency medical situation:
•	 Consider recommending analgesic
•	 Advice patient to clean the injury area by rinsing gently with antiseptic
•	 Remove a foreign object if present in the mouth
•	 Apply ice packs to soft tissue injury/swelling
•	 Press with a finger to stop bleedings
•	 Refer to emergency care if symptoms get worse
Avulsed, displaced or fractured teeth o For the permanent tooth: Apply desensitizing-toothpaste on the exposed 
dentin if the fracture involves only enamel or dentin and advised a patient to 
use a temporary emergency filling. Suggest a patient purchase at pharmacy 
or online
o For the primary tooth: Advice appropriate analgesic and take a soft diet
o If the permanent tooth has been knocking-out: Advise patient to put a tooth 
back to the socket by holding its crown part and bite with a handkerchief to 
hold it in its position
o Store the tooth in milk or between check and molar tooth inside the mouth 
and advice patient to find the emergency dental care
CoV-2 is known to be susceptible to oxidation, so 
clinical use of PVP-I 0.2% has been suggested to 
minimize and anticipate transmission of new variant 
corona virus.48 In addition to these applications, 
Parhar et al. in 202049 in their literature review 
suggest dissolving PVP-I up to 0.2% as prophylaxis 
procedures for upper respiratory mucosa of SARS-
CoV-2 cases.
The results of in vitro and in vivo studies as 
well as previous literature reviews were obtained 
from the phenomena that occurred in MERS-CoV 
and SARS-CoV-1 cases. Currently, the results of 
Halodine antiseptic in vitro tests, which is a polymer-
enriched povidone-iodine, have shown a high 
viricidal power against SARS-CoV-2. The result of in 
vitro tests on this virus shows Halodine’s significant 
viricidal effect up to 1/20 dilution. This antiseptic is 
formulated as a nasal spray and mouthwash. It has 
a very low antiseptic concentration and is safe for 
mucosal surfaces.50
Cytotoxicity of povidone-iodine 
The cytotoxic effect of PVP-I in oral cavity is lower 
than other mouthwash. Result of cytotoxicity tests 
on L929 fibroblast cells showed that PVP-I is the 
safest mouthwash compared to chlorhexidine 
digluconate (CHex), octenidine dihydrochloride 
(Oct) and polyhexamethylene biguanide (PHMB).51 
PVP-I 0.23% is effective in vitro as an antivirus 
agent against SARS and MERS corona viruses, but 
its in vivo concentration must be controlled. Study 
conducted by Kim et al. in 2015 revealed that PVP-I 
at concentrations of 5% and 10% are ciliotoxic to 
respiratory epithelial cells, meaning that the use 
of mouthwash containing 5% and 10% PVP-I 
has the potential to harm membrane integrity and 
accessories of respiratory epithelial cells.52 
Treatment approach
The use of PVP-I for oral or oropharyngeal wash 
is by diluting it in 1:20 of sterile water or distilled 
water, it is equal a 0.5% final concentration of 
PVP-I in a solution. Its use varies according to the 
status of the patient or healthcare providers, with 
the recommendation to gargle every 2-3 hours or 
4x a day. The use of mouthwash can be optional in 
the treatment of patients without clinical symptoms 
or health care providers in COVID-19 hotspot.45 
Supporting the rationale for the use of antiseptic 
mouthwash, as reported by an otolaryngologist 
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in Philippines, gargling should be done 3 times a 
day for 60 seconds each. Mouthwash should be 
used along with brushing teeth, mucosal surfaces 
of the palate, tonsils, and basis of tongue. These 
activities help to minimize the transfer of virus to the 
lower respiratory tract to lungs. These efforts have 
helped patients to recover from pneumonia caused 
by SARS-CoV-2 infection.7 In addition, gargling 
with antiseptic is logical to be recommended as 
a preventive, prophylactic, or curative measure 
because it evenly smears antiseptic on the entire 
mucosal surface which is the target of SARS-
CoV-2 attachment, especially the tongue mucosal 
epithelium as it has the highest number of cells that 
present ACE2 among other oral mucosal cells.28 As 
a conclusion, gargling with 0.2% povidone-iodine 
is a part of strategic preventive, prophylactic, and 
curative efforts against SARS-CoV-2 infection.
CONCLUSION
Cross-infection of COVID-19 via oral transmission 
of SARS-CoV-2 virus in the salivary droplets and 
aerosol has become a ‘novel challenge’ for dental 
professionals. Dental care providers and health 
care professionals need to be aware and well 
prepared for preventing the transmission of the 
virus and its associated systemic manifestations 
of the disease. In recent predictions toward the 
future of the ‘new normal’ in dental practice a 
shift paradigm is needed in standards of care, 
habitual oral hygiene and infection control. Strictly 
applied, the recommendations and protocols of 
infection prevention and control measures in dental 
management become a necessity to block the 
cross-infection routes in dental care facilities and 
hospitals.
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